VKTX - What's Going On With Viking Therapeutics Stock On Tuesday? | Benzinga
Viking Therapeutics Inc (NASDAQ:VKTX) released 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).
As previously reported, the study achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 compared to placebo.
The results announced highlight the achievement of secondary endpoints evaluating histologic changes assessed by hepatic biopsy after 52 weeks of treatment with VK2809.
Also Read: Viking Therapeutics’ Weight Loss ...